BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31240875)

  • 1. Clinicopathological and mutational analyses of colorectal cancer with mutations in the POLE gene.
    Hino H; Shiomi A; Kusuhara M; Kagawa H; Yamakawa Y; Hatakeyama K; Kawabata T; Oishi T; Urakami K; Nagashima T; Kinugasa Y; Yamaguchi K
    Cancer Med; 2019 Aug; 8(10):4587-4597. PubMed ID: 31240875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation.
    Hühns M; Nürnberg S; Kandashwamy KK; Maletzki C; Bauer P; Prall F
    Mod Pathol; 2020 Jun; 33(6):1220-1231. PubMed ID: 31857678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors.
    Lee M; Eng G; Barbari SR; Deshpande V; Shcherbakova PV; Gala MK
    Clin Transl Gastroenterol; 2020 Mar; 11(3):e00149. PubMed ID: 32352724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy.
    Ahn SM; Ansari AA; Kim J; Kim D; Chun SM; Kim J; Kim TW; Park I; Yu CS; Jang SJ
    Oncotarget; 2016 Oct; 7(42):68638-68649. PubMed ID: 27612425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East.
    Siraj AK; Bu R; Iqbal K; Parvathareddy SK; Masoodi T; Siraj N; Al-Rasheed M; Kong Y; Ahmed SO; Al-Obaisi KAS; Victoria IG; Arshad M; Al-Dayel F; Abduljabbar A; Ashari LH; Al-Kuraya KS
    Mol Genet Genomic Med; 2020 Aug; 8(8):e1368. PubMed ID: 32567205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morphological, immunophenotypical and molecular features of hypermutation in colorectal carcinomas with mutations in DNA polymerase ε (POLE).
    Forgó E; Gomez AJ; Steiner D; Zehnder J; Longacre TA
    Histopathology; 2020 Feb; 76(3):366-374. PubMed ID: 31479159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. POLE somatic mutations in advanced colorectal cancer.
    Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
    Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and epigenetic features of colorectal cancer patients with somatic POLE proofreading mutations.
    Kawai T; Nyuya A; Mori Y; Tanaka T; Tanioka H; Yasui K; Toshima T; Taniguchi F; Shigeyasu K; Umeda Y; Fujiwara T; Okawaki M; Yamaguchi Y; Goel A; Nagasaka T
    Clin Epigenetics; 2021 May; 13(1):117. PubMed ID: 34034807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
    Fang H; Barbour JA; Poulos RC; Katainen R; Aaltonen LA; Wong JWH
    PLoS Genet; 2020 Feb; 16(2):e1008572. PubMed ID: 32012149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. POLE and POLD1 screening in 155 patients with multiple polyps and early-onset colorectal cancer.
    Esteban-Jurado C; Giménez-Zaragoza D; Muñoz J; Franch-Expósito S; Álvarez-Barona M; Ocaña T; Cuatrecasas M; Carballal S; López-Cerón M; Marti-Solano M; Díaz-Gay M; van Wezel T; Castells A; Bujanda L; Balmaña J; Gonzalo V; Llort G; Ruiz-Ponte C; Cubiella J; Balaguer F; Aligué R; Castellví-Bel S
    Oncotarget; 2017 Apr; 8(16):26732-26743. PubMed ID: 28423643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.
    Temko D; Van Gool IC; Rayner E; Glaire M; Makino S; Brown M; Chegwidden L; Palles C; Depreeuw J; Beggs A; Stathopoulou C; Mason J; Baker AM; Williams M; Cerundolo V; Rei M; Taylor JC; Schuh A; Ahmed A; Amant F; Lambrechts D; Smit VT; Bosse T; Graham TA; Church DN; Tomlinson I
    J Pathol; 2018 Jul; 245(3):283-296. PubMed ID: 29604063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns.
    Hu H; Cai W; Wu D; Hu W; Dong Wang L; Mao J; Zheng S; Ge W
    Cancer Med; 2021 Jan; 10(1):135-142. PubMed ID: 33125191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
    Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant Treatment for
    Van Gool IC; Rayner E; Osse EM; Nout RA; Creutzberg CL; Tomlinson IPM; Church DN; Smit VTHBM; de Wind N; Bosse T; Drost M
    Clin Cancer Res; 2018 Jul; 24(13):3197-3203. PubMed ID: 29559562
    [No Abstract]   [Full Text] [Related]  

  • 15. DNA polymerase ε and δ variants drive mutagenesis in polypurine tracts in human tumors.
    Ostroverkhova D; Tyryshkin K; Beach AK; Moore EA; Masoudi-Sobhanzadeh Y; Barbari SR; Rogozin IB; Shaitan KV; Panchenko AR; Shcherbakova PV
    Cell Rep; 2024 Jan; 43(1):113655. PubMed ID: 38219146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps.
    Elsayed FA; Tops CMJ; Nielsen M; Ruano D; Vasen HFA; Morreau H; J Hes F; van Wezel T
    Mol Genet Genomic Med; 2019 Apr; 7(4):e00603. PubMed ID: 30827058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinicopathology and survival characteristics of patients with POLE proofreading mutations in endometrial carcinoma: A systematic review and meta-analysis.
    Jumaah AS; Al-Haddad HS; McAllister KA; Yasseen AA
    PLoS One; 2022; 17(2):e0263585. PubMed ID: 35139130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of colorectal cancer for carriers of a germ-line mutation in POLE or POLD1.
    Buchanan DD; Stewart JR; Clendenning M; Rosty C; Mahmood K; Pope BJ; Jenkins MA; Hopper JL; Southey MC; Macrae FA; Winship IM; Win AK
    Genet Med; 2018 Aug; 20(8):890-895. PubMed ID: 29120461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in POLE and survival of colorectal cancer patients--link to disease stage and treatment.
    Stenzinger A; Pfarr N; Endris V; Penzel R; Jansen L; Wolf T; Herpel E; Warth A; Klauschen F; Kloor M; Roth W; Bläker H; Chang-Claude J; Brenner H; Hoffmeister M; Weichert W
    Cancer Med; 2014 Dec; 3(6):1527-38. PubMed ID: 25124163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity.
    Castellucci E; He T; Goldstein DY; Halmos B; Chuy J
    Oncologist; 2017 May; 22(5):497-502. PubMed ID: 28465371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.